

Assent of Assignees

Statement under 37 CFR 3.73(b)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bradford Van Wagenen et al.

Application No.: 10/699,563

Confirmation No.: 1604

Filed: November 3, 2003

Art Unit: 1625

For: HETEROPOLYCYCLIC COMPOUNDS AND
THEIR USE AS METABOTROPIC
GLUTAMATE RECEPTOR ANTAGONISTS

Examiner: Z. N. Davis

ASSENT OF ASSIGNEES TO INVENTORSHIP CORRECTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This letter is filed as part of a petition under 37 C.F.R. § 1.48(a). The above-identified application is assigned to the following two entities:

First Assignee: NPS PHARMACEUTICALS, INC.

Address: 383 Colorow Drive
Salt Lake City, UT 84108 USA

Second Assignee: ASTRAZENECA AB

Address: SE-151 85 Södertälje, Sweden

A first Assignment by the original inventors to NPS Pharmaceuticals in the parent application USSN 10/076,618 was recorded at Reel 012758 / Frame 0798. Copies of two other executed assignments by newly added inventors and assigning 50% to AstraZeneca AB are also attached.

The Assignees hereby assent to the correction of inventorship described in a Petition to Add Inventors filed with a Request for Continued Examination on December 6, 2005.

I. NAMES AND SIGNATURES OF ASSIGNEES

AstraZeneca AB	By: _____	Date: _____
	Name: _____	
	Title: _____	

II. NAMES AND SIGNATURES OF WITNESSES

Name: _____	Signature: _____	Date: _____
Name: _____	Signature: _____	Date: _____

III. NAMES AND SIGNATURES OF ASSIGNEES

NPS Pharmaceuticals, Inc.	By: <u>Barton W. Giddings</u> Name: Barton W. Giddings Title: Assistant corporate secretary	Date: <u>12-7-2005</u>
---------------------------	---	------------------------

IV. NAMES AND SIGNATURES OF WITNESSES

Name: <u>Leslie Lancaster</u>	Signature: <u>Leslie Lancaster</u>	Date: <u>12-7-2005</u>
Name: <u>Traci McFarland</u>	Signature: <u>Traci McFarland</u>	Date: <u>12-7-2005</u>

STATEMENT UNDER 37 CFR 3.73(b)

Applicant: Bradford Van Wagenen et al.

Application No.: 10/699,563 Filed Date: November 3, 2003

Entitled: HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

NPS PHARMACEUTICALS, Inc. , a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is 50 %
in the patent application/patent identified above by virtue of either:

A. An assignment from the Inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012758,

Frame 0798, and for which a copy thereof is attached. Also attached are copies of two other relevant assignments.

OR

B. A chain of title from the Inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Barton W. Giddings
Signature

4 January 2006
Date

Barton W. Giddings
Printed or Typed Name

801-583-4949
Telephone Number

Assistant Corporate Secretary
Title

Docket No.: 5998-0506PUS3
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bradford Van Wagenen et al.

Application No.: 10/699,563

Confirmation No.: 1604

Filed: November 3, 2003

Art Unit: 1625

For: HETEROPOLYCYCLIC COMPOUNDS AND
THEIR USE AS METABOTROPIC
GLUTAMATE RECEPTOR ANTAGONISTS

Examiner: Z. N. Davis

ASSENT OF ASSIGNEES TO INVENTORSHIP CORRECTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This letter is filed as part of a petition under 37 C.F.R. § 1.48(a). The above-identified application is assigned to the following two entities:

First Assignee: NPS PHARMACEUTICALS, INC.



Address: 383 Colorow Drive
Salt Lake City, UT 84108 USA

Second Assignee: ASTRAZENECA AB

Address: SE-151 85 Södertälje, Sweden

A first Assignment by the original inventors to NPS Pharmaceuticals in the parent application USSN 10/076,618 was recorded at Reel 012758 / Frame 0798. Copies of two other executed assignments by newly added inventors and assigning 50% to AstraZeneca AB are also attached.

The Assignees hereby assent to the correction of inventorship described in a Petition to Add Inventors filed with a Request for Continued Examination on December 6, 2005.

I. NAMES AND SIGNATURES OF ASSIGNEES		
AstraZeneca AB	By:  Name: Bo Hasslev Title: Director IP Finance & IS	Date: _____
II. NAMES AND SIGNATURES OF WITNESSES		
Name: Ann-Sofie Sternås	Signature: 	Date: _____
Name: Sonya Celebioglu	Signature: 	Date: _____

III. NAMES AND SIGNATURES OF ASSIGNEES		
NPS Pharmaceuticals, Inc.	By: _____ Name: Title:	Date: _____
IV. NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date: _____
Name:	Signature:	Date: _____

STATEMENT UNDER 37 CFR 3.73(b)

Applicants: Bradford Van Wagenen et al.

Application No.: 10/699,563 Filed Date: November 3, 2003

Entitled: HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

ASTRAZENECA AB, a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is 50 %
in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012758,
Frame 0798, and for which a copy thereof is attached. Also attached are two other relevant assignments.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.


Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Signature

Date

Bo Hassley
Printed or Typed Name

Telephone Number

Director, IP Finance & Info.
Title

ASSIGNMENT – WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to as "ASSIGNOR") hereby sells, assigns, and transfers, unto each of

AstraZeneca AB
SE-151 85
Södertälje, Sweden

AND

NPS Pharmaceuticals, Inc.
383 Colorow Drive
Salt Lake City, Utah 84108 United States of America

(hereinafter referred to singly and collectively as "ASSIGNEE") their successors and assigns, equal, undivided and joint 50% exclusive rights, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to:

HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS

as set forth in this United States Patent Application Serial No. 10/076,618 filed February 19, 2002, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, including but not limited to the list of applications shown in Table A below, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

TABLE A

<u>Application #:</u>	<u>Filing Date</u>	<u>Country Code</u>
2002306517	19-Aug-2003	AU
PI0207390-0	20-Aug-2003	BR
2,438,991	20-Aug-2003	CA
2221-2005	31-Aug-2005	CL
02808416.0	19-Feb-2002	CN
03071563	20-Aug-2003	CO
02787093.0	19-Sep-2003	EP
04103079.4	30-Apr-2004	HK
W-00200301831	18-Sep-2003	ID
157,491	20-Aug-2003	IL
01328/DELNP/2003	21-Aug-2003	IN
1252/DEL/2003	10-Oct-2003	IN
6922	20-Aug-2003	IS
2002-567930	19-Aug-2003	JP
10-2003-7010972	21-Aug-2003	KR
PA/a/2003/007513	21-Aug-2003	MX
20033711	19-Feb-2002	NO
527691	19-Aug-2003	NZ
1-2003-500762	12-Aug-2003	PH
P-369598	20-Aug-2003	PL
2003128535	22-Sep-2003	RU
200305450-9	19-Aug-2003	SG
2003088019	27-Aug-2003	UA
60/269,847	21-Feb-2001	US
10/076,618	19-Feb-2002	US
10/699,563	03-Nov-2003	US
PCT/US02/04689	19-Feb-2002	WO
2003/6493	20-Aug-2003	ZA

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE,

its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **BIRCH, STEWART, KOLASCH & BIRCH, LLP**, the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **BIRCH, STEWART, KOLASCH & BIRCH, LLP**, do not personally represent ASSIGNOR OR ASSIGNEE's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

<i>NAMES AND SIGNATURES OF ASSIGNEES</i>		
AstraZeneca AB	By: _____ Name: Title:	Date:
<i>NAMES AND SIGNATURES OF WITNESSES</i>		
Name:	Signature:	Date:
Name:	Signature:	Date:

<i>NAMES AND SIGNATURES OF ASSIGNEES</i>		
NPS Pharmaceuticals, Inc.	By: _____ Name: Title:	Date:
<i>NAMES AND SIGNATURES OF WITNESSES</i>		
Name:	Signature:	Date:
Name:	Signature:	Date:

<u>NAMES AND SIGNATURES OF INVENTORS</u>		
Name: Ian EGLE c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature:	Date:
<u>NAMES AND SIGNATURES OF WITNESSES</u>		
Name:	Signature:	Date:
Name:	Signature:	Date:

<u>NAMES AND SIGNATURES OF INVENTORS</u>		
Name: Louise EDWARDS c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature:	Date:
<u>NAMES AND SIGNATURES OF WITNESSES</u>		
Name:	Signature:	Date:
Name:	Signature:	Date:

<u>NAMES AND SIGNATURES OF INVENTORS</u>		
Name: Tomislav STEFANAC c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature:	Date:
<u>NAMES AND SIGNATURES OF WITNESSES</u>		
Name:	Signature:	Date:
Name:	Signature:	Date:

NAMES AND SIGNATURES OF INVENTORS		
Name: Tao XIN c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature:	Date:
NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date:
Name:	Signature:	Date:

NAMES AND SIGNATURES OF INVENTORS		
Name: Jalaj ARORA c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature:	Date:
NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date:
Name:	Signature:	Date:

NAMES AND SIGNATURES OF INVENTORS		
Name: William F. MICHNE c/o AstaZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437 Wilmington, Delaware 19850-5437, USA	Signature: 	Date: 12/23/05
NAMES AND SIGNATURES OF WITNESSES		
Name: Eve Hansen	Signature: Eve Hansen	Date: 12/23/05
Name: Elizabeth A. Michne	Signature: Elizabeth A. Michne	Date: 12/23/05

ASSIGNMENT – WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to as "ASSIGNOR") hereby sells, assigns, and transfers, unto each of

AstraZeneca AB
SE-151 85
Södertälje, Sweden

AND

NPS Pharmaceuticals, Inc.
383 Colorow Drive
Salt Lake City, Utah 84108 United States of America

(hereinafter referred to singly and collectively as "ASSIGNEE") their successors and assigns, equal, undivided and joint 50% exclusive rights, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to:

HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS

as set forth in this United States Patent Application Serial No. 10/076,618 filed February 19, 2002, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, including but not limited to the list of applications shown in Table A below, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

TABLE A

Application #:	Filing Date	Country Code
2002306517	19-Aug-2003	AU
PI0207390-0	20-Aug-2003	BR
2,438,991	20-Aug-2003	CA
2221-2005	31-Aug-2005	CL
02808416.0	19-Feb-2002	CN
03071563	20-Aug-2003	CO
02787093.0	19-Sep-2003	EP
04103079.4	30-Apr-2004	HK
W-00200301831	18-Sep-2003	ID
157,491	20-Aug-2003	IL
01328/DELNP/2003	21-Aug-2003	IN
1252/DEL/2003	10-Oct-2003	IN
6922	20-Aug-2003	IS
2002-567930	19-Aug-2003	JP
10-2003-7010972	21-Aug-2003	KR
PA/a/2003/007513	21-Aug-2003	MX
20033711	19-Feb-2002	NO
527691	19-Aug-2003	NZ
1-2003-500762	12-Aug-2003	PH
P-369598	20-Aug-2003	PL
2003128535	22-Sep-2003	RU
200305450-9	19-Aug-2003	SG
2003088019	27-Aug-2003	UA
60/269,847	21-Feb-2001	US
10/076,618	19-Feb-2002	US
10/699,563	03-Nov-2003	US
PCT/US02/04689	19-Feb-2002	WO
2003/6493	20-Aug-2003	ZA

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE,

its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **BIRCH, STEWART, KOLASCH & BIRCH, LLP**, the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.



ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **BIRCH, STEWART, KOLASCH & BIRCH, LLP**, do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

NAMES AND SIGNATURES OF ASSIGNEES		
AstraZeneca AB	By: _____ Name: _____ Title: _____	Date: _____
NAMES AND SIGNATURES OF WITNESSES		
Name: _____	Signature: _____	Date: _____
Name: _____	Signature: _____	Date: _____



NAMES AND SIGNATURES OF ASSIGNEES		
NPS Pharmaceuticals, Inc.	By: <u>Edward F. Nemeth</u> Name: Edward F. Nemeth Title: Chief Scientific Officer	Date: <u>8 Dec 05</u>
NAMES AND SIGNATURES OF WITNESSES		
Name: <u>Teresa A. Beck</u>	Signature: _____	Date: <u>December 8, 2005</u>
Name: <u>Lisowsky Snezana</u>	Signature: <u>Dorothy Snezana</u>	Date: <u>December 8, 2005</u>



NAMES AND SIGNATURES OF INVENTORS		
Name: Ian EGLE c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature: 	Date: Dec. 7 / 05
NAMES AND SIGNATURES OF WITNESSES		
Name: Teresa A. Beck	Signature: Signature	Date: December 7 / 05
Name: Snezana Lisowsky	Signature: Snezana Lisowsky	Date: December 7, 05

NAMES AND SIGNATURES OF INVENTORS		
Name: Louise EDWARDS c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature: 	Date: Dec 7 / 05
NAMES AND SIGNATURES OF WITNESSES		
Name: Teresa A. Beck	Signature: Signature	Date: December 7, 2005
Name: Snezana Lisowsky	Signature: Snezana Lisowsky	Date: December 7, 05

NAMES AND SIGNATURES OF INVENTORS		
Name: Tomislav STEFANAC c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature: 	Date: Dec. 7, 2005
NAMES AND SIGNATURES OF WITNESSES		
Name: Teresa A. Beck	Signature: Signature	Date: December 7, 2005
Name: Dec. 7, 2005 	Signature: Signature	Date: Dec. 7, 2005

TAO XIN

NAMES AND SIGNATURES OF INVENTORS		
Name: Tao XIN c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature: 	Date: Dec. 7. 2005
NAMES AND SIGNATURES OF WITNESSES		
Name: Teresa A. Beck	Signature: 	Date: December 7 05
Name: Lisovský Smežana	Signature: 	Date: December 7, 05

NAMES AND SIGNATURES OF INVENTORS		
Name: Jalaj ARORA c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature: 	Date: Dec. 07/05
NAMES AND SIGNATURES OF WITNESSES		
Name: Teresa A. Beck	Signature: 	Date: December 7, 2005
Name: Dec. 7. 2005	Signature: 	Date: Dec. 7. 2005
TAO XIN		

NAMES AND SIGNATURES OF INVENTORS		
Name: William F. MICHNE c/o AstaZeneca AB SE-151 85 Södertälje, Sweden	Signature: 	Date:
NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date:
Name:	Signature:	Date:

ASSIGNMENT – WORLDWIDE

Whereas, the inventors, Bradford C. VAN WAGENEN, Thomas M. STORMANN, Scott T. MOE, Susan M. SHEEHAN, Donald A. MCLEOD, Daryl M. SMITH all of Salt Lake City, Utah in the United States; and Methvin B. ISAAC, and Abdelmalik SLASSI of Mississauga, Ontario, Canada, by an assignment recorded April 2, 2002 at Reel 012758, Frames 0798-0800, have assigned their full and exclusive right in and to the invention set forth in U.S. Application Serial No. 10/076,618 filed February 19, 2002 and entitled HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS to: NPS Pharmaceuticals, Inc., 383 Colorow Drive, Salt Lake City, Utah 84108 United States of America, this present address of NPS Pharmaceuticals having changed from 420 Chipeta Way, Salt Lake City, Utah, USA;

Now, therefore, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned acting with proper authority on behalf of NPS Pharmaceuticals, Inc., 383 Colorow Drive, Salt Lake City, Utah 84108 United States of America (hereinafter referred to as "ASSIGNOR") hereby sells, assigns, and transfers, unto

AstraZeneca AB
SE-151 85
Södertälje, Sweden

(hereinafter referred to as "ASSIGNEE") its successors and assigns, equal, undivided and joint 50% exclusive rights, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to:

HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS

as set forth in this United States Patent Application Serial No. 10/076,618 filed February 19, 2002, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, including but not limited to the list of applications shown in Table A below, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

TABLE A

<u>Application #:</u>	<u>Filing Date</u>	<u>Country Code</u>
2002306517	19-Aug-2003	AU
PI0207390-0	20-Aug-2003	BR
2,438,991	20-Aug-2003	CA
2221-2005	31-Aug-2005	CL
02808416.0	19-Feb-2002	CN
03071563	20-Aug-2003	CO
02787093.0	19-Sep-2003	EP
04103079.4	30-Apr-2004	HK
W-00200301831	18-Sep-2003	ID
157,491	20-Aug-2003	IL
01328/DELNP/2003	21-Aug-2003	IN
1252/DEL/2003	10-Oct-2003	IN
6922	20-Aug-2003	IS
2002-567930	19-Aug-2003	JP
10-2003-7010972	21-Aug-2003	KR
PA/a/2003/007513	21-Aug-2003	MX
20033711	19-Feb-2002	NO
527691	19-Aug-2003	NZ
1-2003-500762	12-Aug-2003	PH
P-369598	20-Aug-2003	PL
2003128535	22-Sep-2003	RU
200305450-9	19-Aug-2003	SG
2003088019	27-Aug-2003	UA
60/269,847	21-Feb-2001	US
10/076,618	19-Feb-2002	US
10/699,563	03-Nov-2003	US
PCT/US02/04689	19-Feb-2002	WO
2003/6493	20-Aug-2003	ZA

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to

ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **BIRCH, STEWART, KOLASCH & BIRCH, LLP**, the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **BIRCH, STEWART, KOLASCH & BIRCH, LLP**, do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

NAMES AND SIGNATURES OF ASSIGNOR		
NPS Pharmaceuticals, Inc.	By: <u>Barton W. Giddings</u> Name: Barton W. Giddings Title: Assistant Corporate Secretary	Date: 12-7-2005
NAMES AND SIGNATURES OF WITNESSES		
Name: Leslie Lancaster	Signature: <u>Leslie Lancaster</u>	Date: 12-7-2005
Name: Traci McFarland	Signature: <u>Traci McFarland</u>	Date: 12-7-2005

NAMES AND SIGNATURES OF ASSIGNEE		
AstraZeneca AB	By: _____ Name: Title:	Date:
NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date:
Name:	Signature:	Date:

ASSIGNMENT – WORLDWIDE

Whereas, the inventors, Bradford C. VAN WAGENEN, Thomas M. STORMANN, Scott T. MOE, Susan M. SHEEHAN, Donald A. MCLEOD, Daryl M. SMITH all of Salt Lake City, Utah in the United States; and Methvin B. ISAAC, and Abdelmalik SLASSI of Mississauga, Ontario, Canada, by an assignment recorded April 2, 2002 at Reel 012758, Frames 0798-0800, have assigned their full and exclusive right in and to the invention set forth in U.S. Application Serial No. 10/076,618 filed February 19, 2002 and entitled HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS to: NPS Pharmaceuticals, Inc., 383 Colorow Drive, Salt Lake City, Utah 84108 United States of America, this present address of NPS Pharmaceuticals having changed from 420 Chipeta Way, Salt Lake City, Utah, USA;

Now, therefore, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned acting with proper authority on behalf of NPS Pharmaceuticals, Inc., 383 Colorow Drive, Salt Lake City, Utah 84108 United States of America (hereinafter referred to as "ASSIGNOR") hereby sells, assigns, and transfers, unto

AstraZeneca AB
SE-151 85
Södertälje, Sweden

(hereinafter referred to as "ASSIGNEE") its successors and assigns, equal, undivided and joint 50% exclusive rights, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to:

HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS

as set forth in this United States Patent Application Serial No. 10/076,618 filed February 19, 2002, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, including but not limited to the list of applications shown in Table A below, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

TABLE A

Application #:	Filing Date	Country Code
2002306517	19-Aug-2003	AU
PI0207390-0	20-Aug-2003	BR
2,438,991	20-Aug-2003	CA
2221-2005	31-Aug-2005	CL
02808416.0	19-Feb-2002	CN
03071563	20-Aug-2003	CO
02787093.0	19-Sep-2003	EP
04103079.4	30-Apr-2004	HK
W-00200301831	18-Sep-2003	ID
157,491	20-Aug-2003	IL
01328/DELNP/2003	21-Aug-2003	IN
1252/DEL/2003	10-Oct-2003	IN
6922	20-Aug-2003	IS
2002-567930	19-Aug-2003	JP
10-2003-7010972	21-Aug-2003	KR
PA/a/2003/007513	21-Aug-2003	MX
20033711	19-Feb-2002	NO
527691	19-Aug-2003	NZ
1-2003-500762	12-Aug-2003	PH
P-369598	20-Aug-2003	PL
2003128535	22-Sep-2003	RU
200305450-9	19-Aug-2003	SG
2003088019	27-Aug-2003	UA
60/269,847	21-Feb-2001	US
10/076,618	19-Feb-2002	US
10/699,563	03-Nov-2003	US
PCT/US02/04689	19-Feb-2002	WO
2003/6493	20-Aug-2003	ZA

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including



evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **BIRCH, STEWART, KOLASCH & BIRCH, LLP**, the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **BIRCH, STEWART, KOLASCH & BIRCH, LLP**, do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

NAMES AND SIGNATURES OF ASSIGNOR		
NPS Pharmaceuticals, Inc.	By: _____ Name: Title:	Date:
NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date:
Name:	Signature:	Date:

NAMES AND SIGNATURES OF ASSIGNEE		
AstraZeneca AB	By:  Name: Bo Hasslev Title: Director IP Finance & IS	Date:
NAMES AND SIGNATURES OF WITNESSES		
Name: Ann-Sofie Sternås	Signature: 	Date:
Name: Sonya Celebioglu	Signature: 	Date:



JUNE 04, 2002

PTAS

Commissioner for Trademarks
Arlington, VA 22202-3513
www.uspto.gov

FOLEY & LARDNER
STEPHEN A. BENT
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-5143



102049037A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 04/04/2002

REEL/FRAME: 012758/0798
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

VAN WAGENEN, BRADFORD C.

DOC DATE: 03/08/2002

ASSIGNOR:

STORMANN, THOMAS M.

DOC DATE: 03/08/2002

ASSIGNOR:

MOE, SCOTT T.

DOC DATE: 03/26/2002

ASSIGNOR:

SHEEHAN, SUSAN M.

DOC DATE: 03/14/2002

ASSIGNOR:

MCLEOD, DONALD A.

DOC DATE: 03/27/2002

ASSIGNOR:

SMITH, DARY L.

DOC DATE: 03/12/2002

ASSIGNOR:

ISAAC, METHVIN B.

DOC DATE: 03/05/2002

ASSIGNOR:
SLASSI, ABDELMALIK

DOC DATE: 03/05/2002

ASSIGNEE:
NPS PHARMACEUTICALS, INC.
420 CHIPETA WAY
SALT LAKE CITY, UTAH 84108-1256

SERIAL NUMBER: 10076618
PATENT NUMBER:

FILING DATE: 02/19/2002
ISSUE DATE:

DOROTHY RILEY, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor has sold and assigned, and by these presents hereby sells and assigns, unto

NPS PHARMACEUTICALS, INC.
420 Chipeta Way
Salt Lake City, Utah 84108-1256

its successors and assigns, the entire right, title and interest, so far as concerns the United States and the Territories and Possessions thereof and all foreign countries in and to the invention in

HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS








as set forth in this United States Patent Application

- executed concurrently herewith
- executed on _____
- Serial No. _____ filed February 19, 2002

said application for United States Letters Patent, including all divisional, renewal, substitute, continuation and Convention applications based in whole or in part upon said inventions or upon said applications, and any and all Letters Patent and reissues and extensions of Letters Patent granted for said inventions or upon said applications and every priority right that is or may be predicated upon or arise from said inventions, said applications, and said Letters Patent; said Assignee being hereby authorized to file patent applications in any or all countries on any or all said inventions in the name of the undersigned or in the name of said Assignee or otherwise as said Assignee may deem advisable, under the International Convention or otherwise; the Commissioner of Patents and Trademarks of the United States of America being hereby authorized to issue or transfer all said Letters Patent to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the undersigned, but also that such assigned right is not encumbered by any grant, license, or other right theretofore given, and that the undersigned will do all acts reasonably serving to ensure that the said inventions, patent applications and Letters Patent shall be held and enjoyed by said Assignee as fully and entirely as the same could have been held and enjoyed by the undersigned if this assignment had not been made, and particularly to execute and deliver to said Assignee all lawful documents including petitions, specifications, oaths, assignments, invention disclaimers, and lawful affidavits in form and substance which may be requested by said Assignee, to furnish said Assignee with all facts relating to said inventions or the history thereof and any and all documents, photographs, models, samples or other physical exhibits which may be of said inventions, and to testify in any proceedings relating to said inventions, patent applications and Letters Patent.

ASSIGNMENT - WORLDWIDE
Attorney Docket No. 085747/0207

The undersigned hereby grant the firm of **FOLEY & LARDNER** the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

NAMES AND SIGNATURES OF INVENTORS		
Name: Bradford C. Van Wagenen	Signature: 	Date: March 8, 2002
Name: Thomas M. Stormann	Signature: 	Date: March 8, 2002
Name: Scott T. Moe	Signature: 	Date: 3-26-02
Name: Susan M. Sheehan	Signature: 	Date: March 14, 2002
Name: Donald A. McLeod	Signature: 	Date: 27 March 2002
Name: Daryl L. Smith	Signature: 	Date: 12 March 2002
Name: Methvin B. Isaac	Signature: 	Date: 5th March 2002
Name: Abdelmalik Slassi	Signature: 	Date: March 08/2002
Name:	Signature:	Date:
Name:	Signature:	Date:
NAMES AND SIGNATURES OF WITNESSES		
Name: Leslie S. Lancaster	Signature: 	Date: 8 March 2002
Name: Leslie S. Lancaster	Signature: 	Date: 27 March 2002

Note: Prima facie evidence of execution may optionally be obtained by execution of this document before a U.S. Consul or before a local officer authorized to administer oaths whose authority is proved by a certificate from a U.S. Consul.

C

IPT-407:4/90(1)(modified)

04-10-2002



102049037

To the Director of the United States Patent and Trademark Office: Please record the attached original documents or copies thereof.

1. Name of conveying party(ies):

Bradford C. Van Wagenen (March 8, 2002)
 Thomas M. Stommann (March 8, 2002)
 Scott T. Moe (March 26, 2002)
 Susan M. Sheehan (March 14, 2002)
 Donald A. McLeod (March 27, 2002)
 Daryl L. Smith (March 12, 2002)
 Methvin B. Isaac (March 5, 2000)
 Abdelmalik Slassi (March 5, 2002)

Additional conveying party(ies)

NO

2. Name and address of receiving party(ies):

NPS PHARMACEUTICALS, INC.
 420 Chipeta Way
 Salt Lake City, Utah 84108-1256

3. Nature of conveyance:

ASSIGNMENT

Execution Date:

See Above

Additional name(s) & address(es)
attached?

NO

4. Application number(s) or patent number(s):

If this is being filed together with a new application, the execution date of the application is:

A. Patent Application Number(s):

B. Patent Number(s):

Additional numbers attached? NO

5. Name and address of party to whom correspondence concerning document should be mailed:

Stephen A. Bent
 FOLEY & LARDNER
 Washington Harbour
 3000 K Street, N.W., Suite 500
 Washington, D.C. 20007-5143

6. Total number of applications/patents involved: 1

7. Total fee (37 C.F.R. § 3.41): \$40.00

 Check Enclosed

Charge to deposit account

8. Deposit account number: 19-0741

DO NOT USE THIS SPACE

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. The Commissioner is hereby authorized to charge any additional recordation fees which may be required in this matter to the above-identified deposit account.

Stephen A. Bent

April 4, 2002

Name of person signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: 3